TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 10740553

Group type: EXPERIMENTAL
Intervention: 1% ropivacaine
Number of subjects: 90

Group type: COMPARATOR
Intervention: 0.75% bupivacaine and 2% lidocaine mixture
Number of subjects: 90
Study: 9217906

Group type: EXPERIMENTAL
Intervention: Training video on death certification
Number of subjects: 185
Study: 1394916

Group type: EXPERIMENTAL
Intervention: albendazole (400mg, single dose)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: mebendazole composite (mebendazole 100 mg and levamisole 25mg bid x 3d)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: oxantel pyrantel pamoate composite (pyrantel pamoate 150 mg and oxantel pamoate 150 mg bid x 2d)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: pyrantel pamoate composite (base 10 mg/kg, single dose)
Number of subjects: 0
Study: 3966851

Group type: EXPERIMENTAL
Intervention: Individual treatment groups with negative affective style (AS)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Home-based family treatment groups with negative affective style (AS)
Number of subjects: 0
Study: 29039979

Group type: EXPERIMENTAL
Intervention: HLD200 (54 mg)
Number of subjects: 41
Study: 25851842

Group type: EXPERIMENTAL
Intervention: 4-hour educational training focused on communication skills
Number of subjects: 45

Group type: COMPARATOR
Intervention: Usual care by GPs in control group
Number of subjects: 45
Study: 24776175

Group type: EXPERIMENTAL
Intervention: Health coaching (12 months)
Number of subjects: 441

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 441
Study: 22327707

Group type: EXPERIMENTAL
Intervention: Vigabatrin (0.5 g twice-daily, enteric)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control
Number of subjects: 20
Study: 20206794

Group type: EXPERIMENTAL
Intervention: Prasugrel 30 mg
Number of subjects: 32

Group type: COMPARATOR
Intervention: Clopidogrel 300 mg
Number of subjects: 32
Study: 17826582

Group type: EXPERIMENTAL
Intervention: Physical activity intervention
Number of subjects: 424

Group type: COMPARATOR
Intervention: Non-exercise educational intervention
Number of subjects: 424
Study: 16047921

Group type: EXPERIMENTAL
Intervention: Exogenous LH activity in the form of human menotrophin
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Exogenous LH activity in the form of human recombinant LH
Number of subjects: 68

Group type: COMPARATOR
Intervention: Pure recombinant FSH
Number of subjects: 68
Study: 12381797

Group type: EXPERIMENTAL
Intervention: Unsupervised active and passive range‐of‐motion exercises
Number of subjects: 19

Group type: COMPARATOR
Intervention: Control group (no intervention specified)
Number of subjects: 19
Study: 11051233

Group type: EXPERIMENTAL
Intervention: DFMO-PCV (alpha-difluoromethylornithine-procarbazine, N-(2-chloroethyl)-N'-cyclohexyl-N-nitrosurea, vincristine)
Number of subjects: 272

Group type: COMPARATOR
Intervention: PCV (procarbazine, N-(2-chloroethyl)-N'-cyclohexyl-N-nitrosurea, vincristine)
Number of subjects: 272

Group type: EXPERIMENTAL
Intervention: DFMO-PCV
Number of subjects: 272

Group type: COMPARATOR
Intervention: PCV
Number of subjects: 272
Study: 9124670

Group type: EXPERIMENTAL
Intervention: Propofol 1 ml (10 mg)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Intralipid 1 ml (control group)
Number of subjects: 58
Study: 8477961

Group type: EXPERIMENTAL
Intervention: Oxandrolone with enteral food supplement
Number of subjects: 273

Group type: COMPARATOR
Intervention: Adequate caloric intake
Number of subjects: 273
Study: 3535612

Group type: EXPERIMENTAL
Intervention: Quinine-urethane formiate
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Quinine lactic acid formiate
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Quinine resorcine hydrochloride
Number of subjects: 9
Study: 31723080

Group type: EXPERIMENTAL
Intervention: Hybrid training system (HTS)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Standard rehabilitation (Control)
Number of subjects: 53
Study: 30264073

Group type: EXPERIMENTAL
Intervention: Tea or cocoa flavanols (exact dosage and duration not specified)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High cocoa treatment (exact dosage and duration not specified)
Number of subjects: 0
Study: 26721220

Group type: EXPERIMENTAL
Intervention: Citron syrup (15 ml, three times daily for 4 weeks)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Propranolol (20 mg tablet, three times daily for 4 weeks)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo syrup (15 ml, three times daily for 4 weeks)
Number of subjects: 90
Study: 25373622

Group type: EXPERIMENTAL
Intervention: UDP‐glucuronosyltransferase phenotype for COT
Number of subjects: 260
Study: 22659448

Group type: EXPERIMENTAL
Intervention: Agrippal® (trivalent subunit egg-based influenza vaccine)
Number of subjects: 1507

Group type: COMPARATOR
Intervention: Fluvirin® (control vaccine)
Number of subjects: 1507
Study: 20513105

Group type: EXPERIMENTAL
Intervention: Specific strength training (SST)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: General fitness training (GFT)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Reference intervention (REF)
Number of subjects: 62
Study: 18829935

Group type: EXPERIMENTAL
Intervention: Femoral nerve block (20 mL of 0.5% bupivacaine) along with standard pain management
Number of subjects: 54

Group type: COMPARATOR
Intervention: Standard pain management alone (typically intravenous narcotics)
Number of subjects: 54
Study: 15812204

Group type: EXPERIMENTAL
Intervention: 10-core biopsy (including 2 additional median cores)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Sextant biopsy (6 cores)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: 10-core biopsy
Number of subjects: 200

Group type: COMPARATOR
Intervention: Sextant biopsy
Number of subjects: 200
Study: 12459648

Group type: EXPERIMENTAL
Intervention: Interleukin-2, interferon-alpha, and cisplatin
Number of subjects: 35
Study: 10333914

Group type: EXPERIMENTAL
Intervention: Lispro insulin injected at -30 min before meal
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Lispro insulin injected at -15 min before meal
Number of subjects: 12

Group type: COMPARATOR
Intervention: Lispro insulin injected at 0 min (at meal)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Lispro insulin injected at +15 min after meal
Number of subjects: 12
Study: 7503007

Group type: EXPERIMENTAL
Intervention: Spironolactone (50 to 100 mg/day, titrated to blood pressure and plasma potassium)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study: 1959704

Group type: EXPERIMENTAL
Intervention: Loxiglumide (22 mumol.kg‐1.h‐1)
Number of subjects: 5

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5
Study: 30426192

Group type: EXPERIMENTAL
Intervention: CSEA with PCEA with EA (group 1)
Number of subjects: 127

Group type: COMPARATOR
Intervention: CSEA with PCEA (group 2)
Number of subjects: 127
Study: 28857658

Group type: EXPERIMENTAL
Intervention: Minocycline (100 mg once daily, increased to 200 mg after 2 weeks)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Minocycline
Number of subjects: 41
Study: 26394126

Group type: EXPERIMENTAL
Intervention: 5-h ENERGY® shot (5-HES)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 23415635

Group type: EXPERIMENTAL
Intervention: Intracoronary adenosine 60 μg
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Intracoronary adenosine 300 μg
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Intracoronary adenosine 600 μg
Number of subjects: 102
Study: 21035513

Group type: EXPERIMENTAL
Intervention: Exercise with high saturated fat diet (SE)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Exercise with high monounsaturated fat diet (UE)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Sedentary with high saturated fat diet (SS)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Sedentary with high monounsaturated fat diet (US)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Exercise (SE and UE)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Sedentary (SS and US)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: All treatments
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: High saturated or unsaturated fat diets
Number of subjects: 8
Study: 19738091

Group type: EXPERIMENTAL
Intervention: Low-dose dopamine (4 mug/kg/min)
Number of subjects: 487

Group type: COMPARATOR
Intervention: Control (no dopamine treatment)
Number of subjects: 487
Study: 18178916

Group type: EXPERIMENTAL
Intervention: Duodenal-jejunal bypass sleeve
Number of subjects: 1
Study: 15089903

Group type: EXPERIMENTAL
Intervention: Low-fat, high-fiber, high vegetable and fruit diet
Number of subjects: 119

Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 119
Study: 11226092

Group type: EXPERIMENTAL
Intervention: Hypertonic saline
Number of subjects: 31

Group type: COMPARATOR
Intervention: Lactated Ringer's solution
Number of subjects: 31
Study: 9745163

Group type: EXPERIMENTAL
Intervention: Emergency medical services (EMS) ambulance transport
Number of subjects: 37889

Group type: EXPERIMENTAL
Intervention: Triage categories 1 and 2
Number of subjects: 37889

Group type: EXPERIMENTAL
Intervention: Triage category 4 (pseudoemergency)
Number of subjects: 37889

Group type: EXPERIMENTAL
Intervention: Advanced life support, referral cases, and ICU bed requirements
Number of subjects: 37889

Group type: EXPERIMENTAL
Intervention: ICU admission
Number of subjects: 37889

Group type: EXPERIMENTAL
Intervention: Case disposition evaluation
Number of subjects: 37889
Study: 7519132

Group type: EXPERIMENTAL
Intervention: Aprotinin (2 x 10(6) KIU bolus followed by 0.5 x 10(6) KIU/h continuous infusion)
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Aprotinin
Number of subjects: 109

Group type: COMPARATOR
Intervention: DDAVP (0.3 micrograms/kg i.v. on completion of CPB)
Number of subjects: 109

Group type: COMPARATOR
Intervention: DDAVP (two doses: first as in group B and an additional dose 6 hours after surgery)
Number of subjects: 109

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 109
Study: 2846291

Group type: EXPERIMENTAL
Intervention: Pancuronium
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Suxamethonium
Number of subjects: 55
Study: 1097149

Group type: EXPERIMENTAL
Intervention: Smoking marihuana
Number of subjects: 10

Group type: COMPARATOR
Intervention: Smoking placebo marihuana
Number of subjects: 10
Study: 31710176

Group type: EXPERIMENTAL
Intervention: Early hard palate closure (EHPC) group
Number of subjects: 108

Group type: COMPARATOR
Intervention: Late hard palate closure (LHPC) group
Number of subjects: 108
Study: 30527940

Group type: COMPARATOR
Intervention: Use of one stent
Number of subjects: 2652

Group type: EXPERIMENTAL
Intervention: Use of two or three stents
Number of subjects: 2652

Group type: EXPERIMENTAL
Intervention: Use of multiple stents (two or three)
Number of subjects: 2652

Group type: COMPARATOR
Intervention: Overall CAS procedures
Number of subjects: 2652
Study: 28351159

Group type: EXPERIMENTAL
Intervention: Computer-assisted support (Phoneme Factory Sound Sorter [PFSS] - Australian version]
Number of subjects: 63
Study: 25944732

Group type: EXPERIMENTAL
Intervention: Darbepoetin-α (High Hb group)
Number of subjects: 321

Group type: COMPARATOR
Intervention: Epoetin-α (Low Hb group)
Number of subjects: 321

Group type: EXPERIMENTAL
Intervention: Both groups (stage 4 CKD)
Number of subjects: 321
Study: 25726677

Group type: EXPERIMENTAL
Intervention: Gemifloxacin
Number of subjects: 156

Group type: COMPARATOR
Intervention: Other fluoroquinolones
Number of subjects: 156
Study: 21771973

Group type: EXPERIMENTAL
Intervention: sRAGE
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: esRAGE
Number of subjects: 0

Group type: COMPARATOR
Intervention: Atorvastatin, 10 mg daily
Number of subjects: 0
Study: 18957811

Group type: EXPERIMENTAL
Intervention: Controlled-release nifedipine (nifedipine CR) plus valsartan
Number of subjects: 0

Group type: COMPARATOR
Intervention: Amlodipine plus valsartan
Number of subjects: 0
Study: 17276962

Group type: EXPERIMENTAL
Intervention: Tibolone (2.5 mg/d)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Tibolone
Number of subjects: 40
Study: 12677545

Group type: EXPERIMENTAL
Intervention: gamma‐hydroxybutyrate
Number of subjects: 28

Group type: COMPARATOR
Intervention: chlorprothixene/phenobarbital
Number of subjects: 28
Study: 11078308

Group type: EXPERIMENTAL
Intervention: Home-based combined walking and resistance exercise program
Number of subjects: 40
Study: 8832446

Group type: EXPERIMENTAL
Intervention: Forced-air warming (convection)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Warmed cotton blankets (conduction)
Number of subjects: 47
Study: 1427804

Group type: EXPERIMENTAL
Intervention: Fleroxacin 400 mg (single oral dose)
Number of subjects: 260

Group type: COMPARATOR
Intervention: Penicillin G (2.4 or 5.0 mega units) plus probenecid 1 gram (single intramuscular and oral dose respectively)
Number of subjects: 260
Study: 6535843

Group type: EXPERIMENTAL
Intervention: Professional psychotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Early treatment in the program
Number of subjects: 0
Study: 31625480

Group type: COMPARATOR
Intervention: 2‐iminobiotin (2‐IB) 0.6 mg/kg, infused over periods between 15 min and 4 h, and repeated doses escalating from 0.6 mg/kg to 12 mg/kg every 4 h for 6 administrations.
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: 2‐iminobiotin (2‐IB) with Captisol® as a solubilizing agent.
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo, infused over the same periods as 2‐IB.
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Repeated iv dosing of 2‐IB in an acute peripheral hypoxic ischemia model.
Number of subjects: 18
Study: 30125688

Group type: EXPERIMENTAL
Intervention: Daily medication group (PrEP)
Number of subjects: 331
Study: 29949330

Group type: EXPERIMENTAL
Intervention: Xuebijing injection
Number of subjects: 0

Group type: COMPARATOR
Intervention: 0.9% sodium chloride injection (Control)
Number of subjects: 0
Study: 24162556

Group type: EXPERIMENTAL
Intervention: Thrice-weekly exercise training (ME = 14) for 8 weeks
Number of subjects: 50

Group type: COMPARATOR
Intervention: Equal attention without training (MC = 14)
Number of subjects: 50
Study: 22875472

Group type: EXPERIMENTAL
Intervention: Culturally sensitive smoking prevention program
Number of subjects: 2

Group type: COMPARATOR
Intervention: Standard smoking prevention program
Number of subjects: 2
Study: 20533546

Group type: EXPERIMENTAL
Intervention: Canakinumab 150 mg
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Canakinumab (all doses)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Canakinumab
Number of subjects: 200

Group type: COMPARATOR
Intervention: Triamcinolone acetonide 40 mg
Number of subjects: 200
Study: 18272094

Group type: EXPERIMENTAL
Intervention: Clinical case management
Number of subjects: 252

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 252
Study: 15877288

Group type: EXPERIMENTAL
Intervention: Rosiglitazone (4 mg/d) for 6 months
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no rosiglitazone)
Number of subjects: 0
Study: 14749150

Group type: EXPERIMENTAL
Intervention: Oral cobalamin (1000-microg p.o. once daily for 10 days, then once weekly for 4 weeks, then once monthly)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Intramuscular cobalamin (1000-microg i.m. once daily for 10 days, then once weekly for 4 weeks, then once monthly)
Number of subjects: 60
Study: 10642360

Group type: EXPERIMENTAL
Intervention: Intense exercise in upright posture (85% peak oxygen consumption rate)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Control (supine posture)
Number of subjects: 7
Study: 8859934

Group type: COMPARATOR
Intervention: Placebo medication
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Mibefradil 6.25, 12.5, or 25 mg/day
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Mibefradil 50 or 100 mg/day
Number of subjects: 15
Study: 1516991

Group type: EXPERIMENTAL
Intervention: Asahi polyacrylonitrile membrane
Number of subjects: 7

Group type: COMPARATOR
Intervention: Polysulfone membrane
Number of subjects: 7

Group type: COMPARATOR
Intervention: AN69 polyacrylonitrile membrane
Number of subjects: 7

Group type: COMPARATOR
Intervention: Polyamide membrane
Number of subjects: 7
Study: 6723209

Group type: EXPERIMENTAL
Intervention: Ethanol (BP; 0.5 g/kg body weight) at 21 degrees C
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Ethanol (BP; 0.5 g/kg body weight) at 30 degrees C
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Ethanol (BP; 1.0 g/kg body weight) at 21 degrees C
Number of subjects: 10
Study: 30782909

Group type: EXPERIMENTAL
Intervention: Early de-escalation of empirical carbapenems guided by the βLACTA test results
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard de-escalation of carbapenems after 48-72 hours based on the antibiogram results
Number of subjects: 0
Study: 28625642

Group type: EXPERIMENTAL
Intervention: CODE (cisplatin 25mg/m2 on days 1, 8; doxorubicin 40mg/m2 on day 1; etoposide 80mg/m2 on days 1‐3; vincristine 1mg/m2 on day 8 every 2 weeks)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: AP (amrubicin 40mg/m2 on days 1‐3 and cisplatin 60mg/m2 on day 1 every 3 weeks)
Number of subjects: 75
Study: 25920401

Group type: EXPERIMENTAL
Intervention: Circumferential antral PVI (CPVI) alone (minimal)
Number of subjects: 234

Group type: EXPERIMENTAL
Intervention: CPVI with IVR ablation (maximal)
Number of subjects: 234

Group type: COMPARATOR
Intervention: Minimal group (without IVR ablation)
Number of subjects: 234

Group type: EXPERIMENTAL
Intervention: Minimal group (with IVR ablation)
Number of subjects: 234
Study: 23981402

Group type: EXPERIMENTAL
Intervention: Reflexology
Number of subjects: 385

Group type: EXPERIMENTAL
Intervention: Lay Foot Manipulation (LFM)
Number of subjects: 385

Group type: COMPARATOR
Intervention: Control
Number of subjects: 385
Study: 21911616

Group type: EXPERIMENTAL
Intervention: Nitrate-rich beetroot juice (0.75 L, 9.3 mmol nitrate; H-BR)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Nitrate-depleted beetroot juice (0.75 L, 0.006 mmol nitrate; H-PL)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Control (normoxia; CON)
Number of subjects: 9
Study: 19234816

Group type: EXPERIMENTAL
Intervention: Bupivacaine plus morphine
Number of subjects: 50

Group type: COMPARATOR
Intervention: Bupivacaine alone
Number of subjects: 50
Study: 17009531

Group type: EXPERIMENTAL
Intervention: Integrated method (operation + Chinese medicine + dexamethasone + vitamin E)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Chinese medicine + dexamethasone + vitamin E
Number of subjects: 96
Study: 14643269

Group type: COMPARATOR
Intervention: Amiodarone (200mg orally 3 times a day)
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Amiodarone (200mg orally 3 times a day) plus enalapril (10mg twice a day)
Number of subjects: 145
Study: 11211370

Group type: EXPERIMENTAL
Intervention: Comprehensive preventive intervention for maltreated infants and toddlers in foster care
Number of subjects: 0

Group type: COMPARATOR
Intervention: Comparison group (1991-1994)
Number of subjects: 0
Study: 9455821

Group type: EXPERIMENTAL
Intervention: Unilateral ovarian follicular aspiration
Number of subjects: 31

Group type: COMPARATOR
Intervention: Control (no aspiration)
Number of subjects: 31
Study: 7933438

Group type: COMPARATOR
Intervention: Total parenteral nutrition including a conventional amino acid solution (control group)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Total parenteral nutrition including the same amino acid solution supplemented with glycyl-glutamine (GLN group)
Number of subjects: 17
Study: 3119449

Group type: COMPARATOR
Intervention: Ranitidine (300 mg)
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Misoprostol (800 mcg)
Number of subjects: 79

Group type: COMPARATOR
Intervention: Ranitidine (300 mg) in smokers
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Misoprostol (800 mcg) in smokers
Number of subjects: 79
Study: 30815556

Group type: EXPERIMENTAL
Intervention: Personalized, nudge‐based risk communication intervention (n = 20)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Standard care (n = 20)
Number of subjects: 40
Study: 26526376

Group type: EXPERIMENTAL
Intervention: Burns (55 reported, 10% of all injuries)
Number of subjects: 5148

Group type: EXPERIMENTAL
Intervention: Serious burns (2340 estimated, 39 per 100,000 persons in 2003)
Number of subjects: 5148

Group type: EXPERIMENTAL
Intervention: Individuals aged over 45 years
Number of subjects: 5148

Group type: EXPERIMENTAL
Intervention: Burns involving ≥20% body surface area (19 burns, 35%)
Number of subjects: 5148
Study: 25706948

Group type: EXPERIMENTAL
Intervention: 300 mg pregabalin orally preoperatively
Number of subjects: 48

Group type: COMPARATOR
Intervention: 4 mg diazepam orally as placebo preoperatively
Number of subjects: 48
Study: 23465098

Group type: EXPERIMENTAL
Intervention: Heparin plus a glycoprotein IIb/IIIa inhibitor
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Bivalirudin
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Previous CABG
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Intervention on the saphenous vein graft
Number of subjects: 105
Study: 21481151

Group type: EXPERIMENTAL
Intervention: Uterine artery embolisation (UAE)
Number of subjects: 157

Group type: COMPARATOR
Intervention: Surgery (hysterectomy or myomectomy)
Number of subjects: 157
Study: 19592103

Group type: EXPERIMENTAL
Intervention: Ready-made spectacles (RMS)
Number of subjects: 495
Study: 16433711

Group type: EXPERIMENTAL
Intervention: Continuous subcutaneous insulin infusion (CSII)
Number of subjects: 272

Group type: COMPARATOR
Intervention: NPH-based multiple daily insulin injections (MDI)
Number of subjects: 272
Study: 12945134

Group type: EXPERIMENTAL
Intervention: Millimetric electromagnetic radiation (MER) combined therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pharmacotherapy alone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Combinations with sinusoidal modulated currents
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo electromagnetic radiation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combined therapy with 5.6 mm radiation
Number of subjects: 0
Study: 10618557

Group type: EXPERIMENTAL
Intervention: Intravenous milrinone
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1000
Study: 9357123

Group type: EXPERIMENTAL
Intervention: Biphasic insulin administered twice a day
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (lente insulin)
Number of subjects: 50